Alexander's (ALX)
(Delayed Data from NYSE)
$244.01 USD
-2.39 (-0.97%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $243.15 -0.86 (-0.35%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALX 244.01 -2.39(-0.97%)
Will ALX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALX
Best Income Stocks to Buy for September 18th
New Strong Buy Stocks for September 18th
ALX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Income Stocks to Buy for September 13th
3 Highly Ranked REITs to Buy with Rate Cuts Ahead
Alexander's (ALX) Upgraded to Strong Buy: Here's What You Should Know
Other News for ALX
UBS Keeps Their Hold Rating on Atlas Arteria (MAQAF)
Atlas Arteria Announces H1 2024 Distribution
Atlas Arteria Faces S&P Rating Downgrade
Atlas Arteria Faces Toll Hike Rejection
RBC Capital Remains a Hold on Atlas Arteria (MAQAF)